Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Current Deferred Revenue (2016 - 2018)

Historic Current Deferred Revenue for Neurocrine Biosciences (NBIX) over the last 9 years, with Q1 2018 value amounting to $731000.0.

  • Neurocrine Biosciences' Current Deferred Revenue fell 7942.0% to $731000.0 in Q1 2018 from the same period last year, while for Mar 2018 it was $731000.0, marking a year-over-year decrease of 7942.0%. This contributed to the annual value of $731000.0 for FY2017, which is 7926.83% down from last year.
  • As of Q1 2018, Neurocrine Biosciences' Current Deferred Revenue stood at $731000.0, which was down 7942.0% from $731000.0 recorded in Q4 2017.
  • In the past 5 years, Neurocrine Biosciences' Current Deferred Revenue ranged from a high of $10.2 million in Q4 2015 and a low of $731000.0 during Q2 2017
  • Over the past 5 years, Neurocrine Biosciences' median Current Deferred Revenue value was $3.3 million (recorded in 2015), while the average stood at $3.2 million.
  • In the last 5 years, Neurocrine Biosciences' Current Deferred Revenue soared by 20685.92% in 2015 and then plummeted by 7942.0% in 2018.
  • Over the past 5 years, Neurocrine Biosciences' Current Deferred Revenue (Quarter) stood at $3.3 million in 2014, then soared by 206.86% to $10.2 million in 2015, then crashed by 65.43% to $3.5 million in 2016, then plummeted by 79.27% to $731000.0 in 2017, then changed by 0.0% to $731000.0 in 2018.
  • Its Current Deferred Revenue stands at $731000.0 for Q1 2018, versus $731000.0 for Q4 2017 and $731000.0 for Q3 2017.